adevers events (AEs), n = 14 | severity (CTC v. 3) grade | ||||
---|---|---|---|---|---|
I | II | III | IV | V | |
acneiforme skin rash | 5 (35.7%) | 9 (64.3%) | 1 (7.1%) | ||
conjunctivitis | 1 (7.1%) | ||||
skin fissures | 1 (7.1%) | 1 (7.1%) | |||
mucositis | 2 (14.3%) | 8 (57.1%) | 4 (28.6%) | ||
dysphagia | 5 (35.7%) | 7 (50%) | 1 (7.1%) | ||
weight loss | 1 (7.1%) | 1 (7.1%) | |||
dermatitis | 2 (14.3%) | 6 (42.9%) | 2 (14.3%) | ||
xerostomia | 8 (57.1%) | 5 (35.7%) | |||
laryngeal oedema | 3 (21.4%) | ||||
anemia | 1 (7.1%) | ||||
leukopenia | 1 (7.1%) | ||||
thrombopenia | 1 (7.1%) | ||||
fever | 1 (7.1%) | 1 (7.1%) | |||
hyperkalaemia | 1 (7.1%) | ||||
hypokalaemia | 2 (14.3%) | ||||
hypomagnesiaemia | 3 (21.4%) | ||||
nausea | 5 (35.7%) | ||||
oedema | 7 (50%) | ||||
diarrhoea | 3 (21.4%) | ||||
constipation | 5 (35.7%) | ||||
Serious adverse events (SAEs) | |||||
skin abscess | 1 (7.1%) | ||||
arterial embolism | 1 (7.1%) | ||||
septic shock | 1 (7.1%) | ||||
anaphylactic reaction | 1 (7.1%) | ||||
hospital admission due to tonsillitis | 1 (7.1%) | ||||
death due to progressive metastatic disease | 1 (7.1%) |